IL93271A - 4-Hydroxythiazoles, lipoxygenase enzyme inhibitors - Google Patents

4-Hydroxythiazoles, lipoxygenase enzyme inhibitors

Info

Publication number
IL93271A
IL93271A IL9327190A IL9327190A IL93271A IL 93271 A IL93271 A IL 93271A IL 9327190 A IL9327190 A IL 9327190A IL 9327190 A IL9327190 A IL 9327190A IL 93271 A IL93271 A IL 93271A
Authority
IL
Israel
Prior art keywords
alkyl
group
aryl
arylalkyl
hydrogen
Prior art date
Application number
IL9327190A
Other languages
English (en)
Hebrew (he)
Other versions
IL93271A0 (en
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL93271A0 publication Critical patent/IL93271A0/xx
Publication of IL93271A publication Critical patent/IL93271A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/34—Ethylene-urea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL9327190A 1989-02-08 1990-02-04 4-Hydroxythiazoles, lipoxygenase enzyme inhibitors IL93271A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30817789A 1989-02-08 1989-02-08

Publications (2)

Publication Number Publication Date
IL93271A0 IL93271A0 (en) 1990-11-29
IL93271A true IL93271A (en) 1994-11-11

Family

ID=23192878

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9327190A IL93271A (en) 1989-02-08 1990-02-04 4-Hydroxythiazoles, lipoxygenase enzyme inhibitors

Country Status (11)

Country Link
US (1) US5124342A (el)
EP (1) EP0457803A4 (el)
JP (1) JP2877508B2 (el)
KR (1) KR920701166A (el)
AU (1) AU640637B2 (el)
CA (1) CA2046628A1 (el)
GR (1) GR900100077A (el)
IE (1) IE900394L (el)
IL (1) IL93271A (el)
NZ (1) NZ232369A (el)
WO (2) WO1990009381A1 (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645867B2 (en) * 1990-11-30 1994-01-27 Teijin Pharma Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
US5264361A (en) * 1991-03-18 1993-11-23 Lonza Ltd. Microbiological process for the production of 6-hydroxypicolinic acid
IT1254199B (it) * 1992-02-06 1995-09-14 Ministero Dell Uni E Della Tiazolilpirroli ad attivita' fungicida
US5270203A (en) * 1992-03-13 1993-12-14 Lonza Ltd. Biologically pure culture of Alcaligenes faecalis DSM 6335
BR9507598A (pt) 1994-05-04 1997-10-07 Bayer Ag Tiocarboxamidas aromáticas substituídas e seu uso como herbicidas
USRE39263E1 (en) * 1994-05-04 2006-09-05 Bayer Aktiengesellschaft Substituted aromatic thiocarboxylic acid amides and their use as herbicides
CA2167384A1 (en) 1994-05-16 1995-11-23 Hideki Ushio Process for producing tetrazole compound and intermediate therefor
WO1996031211A1 (fr) * 1995-04-07 1996-10-10 Teijin Limited Agent protecteur pour organe ou tissu
WO1997012613A1 (en) * 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5811425A (en) * 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6492398B1 (en) 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
US6624171B1 (en) * 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
MXPA05000200A (es) 2002-07-02 2005-06-06 Schering Corp Nuevos antagonistas del receptor neuropeptido y y5.
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR101164258B1 (ko) 2003-12-23 2012-07-11 아스텍스 테라퓨틱스 리미티드 단백질 키나아제 조절제로서의 피라졸 유도체
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
EP1933832A2 (en) 2005-06-23 2008-06-25 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
WO2007009083A2 (en) * 2005-07-12 2007-01-18 Acadia Pharmaceuticals Inc. Compounds with activity at retinoic acid receptors
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8158801B2 (en) 2005-09-26 2012-04-17 Life Technologies Corporation Violet laser excitable dyes and their method of use
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
TWI403506B (zh) * 2008-06-16 2013-08-01 Faes Farma Sa 用於治療急性和慢性發炎疾病之５－（４－甲磺醯基－苯基）－噻唑衍生物類
US7781594B2 (en) * 2008-06-16 2010-08-24 Faes Farma, S.A. 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
CA3024556A1 (en) * 2016-05-12 2017-11-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
US11110177B2 (en) 2017-11-10 2021-09-07 The Regents Of The University Of Michigan ASH1L degraders and methods of treatment therewith

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260609A (en) * 1977-06-01 1981-04-07 Merck & Co., Inc. Di- and tri- substituted thiazoles
US4528291A (en) * 1982-06-22 1985-07-09 Schering Corporation 2-(4'-Pyridinyl)-thiazole compounds and their use in increasing cardiac contractility
US4649146A (en) * 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
US4935424A (en) * 1988-05-27 1990-06-19 Warner-Lambert Company 4 or 5-(substituted piperazinylalkyl)-2-aminothiazoles as antipsychotic agents

Also Published As

Publication number Publication date
JPH04503212A (ja) 1992-06-11
WO1990009801A1 (en) 1990-09-07
JP2877508B2 (ja) 1999-03-31
KR920701166A (ko) 1992-08-11
IL93271A0 (en) 1990-11-29
CA2046628A1 (en) 1990-08-09
WO1990009381A1 (en) 1990-08-23
EP0457803A1 (en) 1991-11-27
AU640637B2 (en) 1993-09-02
NZ232369A (en) 1992-01-29
GR900100077A (el) 1991-06-28
AU5181590A (en) 1990-09-26
US5124342A (en) 1992-06-23
IE900394L (en) 1990-08-08
EP0457803A4 (en) 1991-12-04

Similar Documents

Publication Publication Date Title
IL93271A (en) 4-Hydroxythiazoles, lipoxygenase enzyme inhibitors
EP0320628B1 (en) Substituted furan compounds which are useful in inhibiting lipoxygenase enzymes, particularly 5-lipoxygenase
US5391565A (en) Oxazolidine dione derivatives
US5436348A (en) Benzoxazolinonyl substituted alkylamines
AU651388B2 (en) Novel compounds
US20180258079A1 (en) 1,2-naphthoquinone based derivative and method of preparing the same
KR20150088990A (ko) 5,5-헤테로방향족 항-감염 화합물
NZ328900A (en) Substituted phenyl or pyridyl substituted phenyl, benzo[b]furan or indolyl derivatives and medicaments
EP0310370A1 (en) 2-aryl substituted heterocyclic compounds as antiallgeric and anti-inflammatory agents
CA2341970A1 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
EP0611766A1 (fr) Dérivés de 2-amido-thiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament
WO2013075596A1 (zh) 作为dhodh抑制剂的五元二氢杂环酮类衍生物及应用
JP2016128465A (ja) インダノン誘導体、その薬学的に許容される塩又は光学異性体、その調製方法及びそれを活性成分として含有するウイルス疾患の予防又は治療用の医薬組成物
JPH09503792A (ja) 新規なチアゾリジン−４−オン誘導体
US4769387A (en) Dibenzofuran lipoxygenase inhibiting compounds, compositions and use
IE902908A1 (en) Certain benzopyran and benzothiopyran derivatives
US5821242A (en) Anti-viral compounds
US5202349A (en) Substituted phenylacetylenes, pharmaceutical compositions containing these compounds and processes for the preparation of these compounds and compositions
US6087374A (en) Anti-viral compounds
US5023334A (en) Anthelmintic pyridinyl acylhydrazones
US4970210A (en) Triazinone lipoxygenase compounds
EP1879884A1 (en) Azole-based phosphodiesterase inhibitors
CZ453699A3 (cs) Způsob a meziprodukty pro přípravu inhibitorů 5-lipoxygenasy
JPH02167225A (ja) 血糖降下剤

Legal Events

Date Code Title Description
KB Patent renewed
RH Patent void